ClinicalTrials.gg
RecruitingNCT07523997PET-EndoUpdated May 27, 2026

Imaging of Endometriosis With Total-body PET-CT (PET-Endo)

An observational study in Endometriosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by University of Edinburgh · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Endometriosis with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Endometriosis · United Kingdom.

Planned enrollment
10th of 12
30 · median 100
Started
2026
with 1 other
Observational
12 of 25
8 open now
Primary completion
2027-04
later than 5 of 10 live
Registered
24th of 25
by date
Lead sponsor
6 of 25
University of Edinburgh

Among the 25 studies in Endometriosis with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2026, is one of 12 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 24th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

10 of the 25 studies in Endometriosis with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Endometriosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Endometriosis is a disease that affects 1 in 10 women and is associated with debilitating pain and infertility. Endometriosis is where cells similar to those lining the womb (the 'endometrium') grow elsewhere in the body, forming 'lesions'. Most commonly the lesions grow on the lining of the pelvic cavity, called 'peritoneal' endometriosis. Lesions can also grow on the ovary, this is called 'ovarian' endometriosis, or form nodules, called 'deep' endometriosis.

At present the only way to confidently identify endometriosis is through surgery, this exposes patient to the risks of surgery and contributes to the diagnostic delay associated with endometriosis.

PET/CT is a specialist scan that is commonly used to identify cancers which cannot be seen on other types of scans. PET/CT uses a 'tracer', a substance given into a vein which then temporarily accumulates in areas of disease.

This project will determine if a new specialist scan, total body PET/CT, and novel tracers that were developed for other conditions can be used to identify some of the key pathways in endometriosis: bleeding and scarring. Being able to identify these processes in endometriosis lesions and being able to track how they change over time would improve our understanding of endometriosis. The investigators also want to know if these pathways are different between superficial, deep and ovarian endometriosis, and what the impact is of the hormones related to the menstrual cycle.

In this study up to 30 people who have suspected endometriosis and are already due to undergo diagnostic surgery will be asked to undergo two total-body PET/CT scans in Edinburgh, one at one visit and one another visit. Participants will also have a PET/MRI scan at visit. Participants will have a different tracer at each visit. The investigators will then compare the scan findings with their subsequent surgical findings.

Read the detailed description

This will be an observational cohort study using a prospectively recruited cohorts for both cross-sectional and longitudinal comparison across the spectrum of endometriosis subtypes.

Up to 30 participants with a clinical/radiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months will be recruited.

Data collected at baseline includes demographics, clinical history including previous imaging. Participants will complete the WERF EPHect questionnaire

Participants will attend two visits for imaging. They will undergo advanced imaging by total-body positron emission tomography and computed tomography (PET/CT), followed by PET/MRI for anatomical reconciliation of lesions and additional information about tracer dynamics. At one visit 68Ga-FAPI will be administered, and at the other 18F-GP1. IV buscopan will be given prior to the PET/MRI.

Following completion of imaging studies, participants will be invited to complete an online acceptability questionnaire, and complete and optional qualitative interview about their experience.

Subsequent surgical findings and associated histopathology will be correlated with tracer uptake

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • PET-CT
  • PET-MRI
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

30 patients in NHS Lothian with clinically diagnosed endometriosis due to undergo confirmatory laparoscopy in the subsequent four months will be recruited. All subjects recruited for the study will be able to withdraw from the study at any time. The patients will be referred to the study by their treating physicians to investigate clinically diagnosed endometriosis. We will not recruit or enroll healthy volunteers in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic pelvic pain
  • Clinical/radiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months

Exclusion criteria

Exclusion Criteria:

  • Inability or unwilling to give
  • Actively trying to conceive, pregnant or breastfeeding
  • Post menopausal (no periods for >12 months and not taking hormonal treatments to prevent periods or bilateral oophorectomy performed)
  • Previous hysterectomy
  • Confirmed or suspected pelvic
  • to MRI (ferromagnetic material in the body, metallic device implantation or claustrophobia)
  • Contraindication to buscopan (e.g. glaucoma, unstable cardiac disease, arrythmias, myasthenia, previous to buscopan)
  • Taking part in a CTIMP or interventional non-CTIMP study
  • Previous severe pelvic inflammatory disease
  • Previous peritonitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Suspected endometriosis

    Women/those assigned female at birth (aged ≥18 years) with chronic pelvic pain and a clinical/radiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months.

    Diagnostic Test: PET/CT · Diagnostic Test: PET/MRI · Drug: Buscopan 20 MG/ML Injectable Solution

Interventions

  • Diagnostic testPET/CT

    Hybrid positron emission tomography and computed tomography will be performed after intravenous administration of the 68Ga-FAPI or the 18F-GP1 radiotracer and images centred on the pelvis. Attenuation-correction CT will be performed before acquisition of PET data

  • Diagnostic testPET/MRI

    Hybrid PET/MRI will be performed on a 3T scanner with T1 mapping immediately after the PET/CT with images acquired centred on the pelvis after injection of buscopan

  • DrugBuscopan 20 MG/ML Injectable Solution

    Drug page: Butylscopolammonium BromideStudies of Butylscopolammonium BromideButylscopolammonium Bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV injection prior to PET/MRI

    Also known as: 20mg

06

What researchers measure

Primary outcomes

  1. In vivo uptake of 18F-GP1 and 68Ga-FAPI in endometriosis

    Tracer uptake will be quantified by determining standardized uptake values (SUVs) and tissue to background ratio (TBR) in areas of increased uptake within the abdomen. This will correlated with surgical findings, specifically presence and location of endometriosis lesions.

    Time frame: within 3 months post surgery

Secondary outcomes

  1. Non-invasive in vivo imaging-based characterisation of thrombosis and fibrosis characterisation in superficial, ovarian and deep endometriosis lesions

    Tracer uptake will be quantified by determining standardized uptake values (SUVs) and tissue to background ratio (TBR) in areas of increased uptake within the abdomen. The relative values for the two separate tracers GP1 (activated platelets) and FAPI (fibrosis) will be correlated with the macroscopic appearance of lesions of differing subtypes at surgery.

    Time frame: within 3 months post surgery

  2. Acceptability of PET imaging for characterisation of endometriosis

    Bespoke acceptability questionnaire will be administered following surgery. Acceptability of the overall study and specific aspects will be rated on a 5 point Likert scale, with free text options for further detail. Data will summarised despitative, with thematic analysis of free text where able. Additional acceptability data will be derived from qualitative interviews of a purposive sample of participants and analysed thematically.

    Time frame: within 3 months post surgery

07

Study locations

1 of 1 sites recruiting
  • Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh
    Edinburgh, City Of Edinburgh EH16 4UU, United Kingdom
    Recruiting
    • Lucy HR Whitaker, MD · Contactetmt@ed.ac.uk
    • Lucy HR Whitaker, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Requests for anonymised data sharing will be considered on a case by case basis by the trial management team with appropriate data sharing contracts in place

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 13, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Dec 31, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523997
Collaborators
Life Molecular Imaging Ltd
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 8, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Lucy HR Whitaker, MD
Contact
ETMT@ed.ac.uk
01316518321
Lucy HR Whitaker, MD
principal investigator · University of Edinburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion